Immix Biopharma (IMMX) revenue and earnings history
Immix Biopharma's annual figures for 6 fiscal years, as filed with the SEC.
Revenue and net income, 6 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | — | −$30M | — | −$23.9M | $733K | −$24.7M | $2.44M | — | — | $93.9M | — | 10-K/A |
| 2024ended Dec 31, 2024 | — |
The latest quarter, insider trades and fund moves: Immix Biopharma (IMMX) on OQRO.
Common questions
Has Immix Biopharma been profitable?
It reported a net loss in 5 of the years shown (2020, 2021, 2022, 2023, 2024). The highest net income was −$1.15M in fiscal 2020.
What was Immix Biopharma's free cash flow in fiscal 2025?
−$24.7M: operating cash flow of −$23.9M minus capital expenditure of $733K. OQRO calculates free cash flow this way from the two filed lines.
How much cash has Immix Biopharma returned to shareholders?
Its cash-flow statements show $100K on buying back its own shares over 1 fiscal year ($0 in fiscal 2025). These are the dollar amounts paid in each year, as filed; a year with no figure means none was tagged.
Where these figures come from
The SEC’s companyfacts data: every figure Immix Biopharma tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
